Bruce Cohen appointed Executive Chairman and Erik Holmlin joins Board of
TORONTO, Sept. 11, 2012 /CNW/ - Xagenic Inc., a privately held
point-of-care molecular diagnostics company, today announced the
appointment of Bruce A. Cohen as Executive Chairman of the Board, and
that R. Erik Holmlin has been appointed to the Board of Directors.
Mr. Cohen was most recently President and CEO of VitaPath Genetics, a
molecular diagnostics company developing a family of DNA tests to help
individuals reduce the risk of serious and life-threatening disease.
Previously, Bruce spent five years as President and CEO of Cellerant
Therapeutics, a biotechnology company with a portfolio of curative
therapies based on the regulation of the hematopoietic (blood-forming)
system. His earlier industry roles included: CFO of GeneSoft
Pharmaceuticals, President and CEO of Acacia Biosciences, Vice
President at Sequus Pharmaceuticals, and President and COO of Vitel
International, Inc. Bruce brings a wealth of experience in diagnostic
product development, business strategy development and execution.
Dr. Holmlin is President and CEO of BioNano Genomics, a venture-backed
startup leading the introduction of a platform for genome mapping. He
has also recently served as President and CEO of GenVault Corporation,
an Entrepreneur in Residence at Domain Associates, LLC, and Chief
Commercial Officer at Exiqon A/S. In 2001 Erik led the formation of
GeneOhm Sciences, Inc., where he occupied a variety of roles including
Senior Technology Director, Vice President of Technology and Business
Development. He orchestrated GeneOhm's acquisition in 2006 by Becton
Dickinson and then served BD as Vice President of Marketing and
"With the impressive progress Xagenic has made in its product
development program, this system embodies the most promising
point-of-care technology I have seen, in that it can truly disrupt the
current industry model of lab-based, centralized molecular diagnostic
testing," said Mr. Cohen. "I am pleased to be a part of the efforts
the company has undertaken."
"We are excited to have Bruce Cohen and Erik Holmlin joining our Board",
said Xagenic Board member Shermaine Tilley, who is a Partner at CTI
Life Sciences Fund (CTI). "Bruce has a notable career as an
entrepreneur in the healthcare sector. His leadership and management
experience will be a tremendous asset to Xagenic's business as the
company implements its development and commercialization plan,"
continued Dr. Tilley. "Erik has an impressive track record as a life
sciences executive with experience in leading venture backed
Bruce Cohen and Erik Holmlin join current Xagenic Board members Dr.
Shermaine Tilley and Mr. Richard Meadows, both of CTI, and Dr. Shana
Kelley, CTO and Founder of Xagenic.
About Xagenic Inc.
Xagenic Inc. is a Toronto, ON-based, venture-backed start-up molecular
diagnostics company developing a point-of-care testing system. The
company's fully automated technology platform will enable widespread
decentralized diagnostic testing to be performed outside of clinical
testing laboratories. Xagenic is developing infectious disease
diagnostic tests that will allow the detection of a variety of analytes
in situations where rapid test turnaround will provide clinically
actionable results that dramatically improve patient care and reduce
health care costs. More information on Xagenic can be found at www.xagenic.com.
About CTI Life Sciences Fund
CTI is a Montreal-based limited partnership making venture capital
investments in high quality emerging life sciences companies at the
start-up and clinical development stage primarily in Canada. CTI has a
diverse team of professionals in science and finance with extensive
experience in the biotechnology and the pharmaceutical industries. The
Fund works closely with entrepreneurs and researchers to increase the
value of young companies. More information on CTI can be found at www.ctisciences.com.
SOURCE: Xagenic Canada Inc.
For further information:
Shana Kelley, Ph.D.
CTI Life Sciences Fund
Shermaine Tilley, Ph.D, MBA